No Cover Image

E-Thesis 414 views

Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer / AI-MY CHI

Swansea University Author: AI-MY CHI

Full text not available from this repository: check for access using links below.

DOI (Published version): 10.23889/SUthesis.59217

Abstract

Introduction: Prostate cancer is the second most frequent male cancer worldwide. Although prostate cancer is not always life-threatening when confined to the gland, the 5-year survival rate remains poor for men with advanced disease at approximately 30%. For such patients, there is an unmet need for...

Full description

Published: Swansea 2022
Institution: Swansea University
Degree level: Doctoral
Degree name: Ph.D
Supervisor: Doak, Shareen H. ; Conlan, Steve
URI: https://cronfa.swan.ac.uk/Record/cronfa59217
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-01-19T15:46:24Z
last_indexed 2022-01-29T03:42:51Z
id cronfa59217
recordtype RisThesis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-01-27T15:47:28.4614120</datestamp><bib-version>v2</bib-version><id>59217</id><entry>2022-01-19</entry><title>Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer</title><swanseaauthors><author><sid>a64c91cbb998dc0f5a14f291102f75ce</sid><firstname>AI-MY</firstname><surname>CHI</surname><name>AI-MY CHI</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-01-19</date><abstract>Introduction: Prostate cancer is the second most frequent male cancer worldwide. Although prostate cancer is not always life-threatening when confined to the gland, the 5-year survival rate remains poor for men with advanced disease at approximately 30%. For such patients, there is an unmet need for patient-tailored drugs to improve their clinical management and quality of life, since current therapy options are accompanied with severe side-effects. The Six-Transmembrane Epithelial Antigen of the Prostate2 (STEAP2) is a cell surface protein highly expressed in advanced prostate cancer but not in the normal prostate. STEAP2 drives cancer invasive traits associated with prostate cancer progression in vitro and represents a promising drug target. The aim of this thesis was therefore to evaluate, whether STEAP2 is a viable drug target in vitro, with a focus on the application of antibodies (Abs) and Ab-Drug-Conjugates (ADCs), to treat advanced prostate cancer. Methods: Immunohistochemistry (IHC) analysis of tissue-microarrays (TMAs) containing 33 tissues across the human body was conducted to assess the normal tissue profile of STEAP2. Structural analysis of STEAP2 was performed to identify targetable regions for the use of Ab therapeutics. One commercial polyclonal anti-STEAP2 Ab (anti-STEAP2 pAb) was selected for proof-of-concept studies based on the ability to detect both linear and native STEAP2 by confocal microscopy and protein analysis in prostate cancer cells (PC3) and normal prostate epithelial cells (PNT2). The effect of the anti-STEAP2 pAb on cancer invasive traits was studied in PC3 and PNT2 cells. Receptor internalisation of STEAP2 was evaluated upon anti-STEAP2 pAb binding to confirm the suitability of the ADC technology by confocal microscopy. A polyclonal anti-STEAP2-monomethylauristatin-E (MMAE) ADC (anti-STEAP2 pADC) was produced to compare its effect on reducing the cell viability of PC3 cells versus the unconjugated anti-STEAP2 pAb alone. Monoclonal anti-STEAP2 Ab (anti-STEAP2 mAb) was generated by the hybridoma technology using Balb/C mice. The specificity of the mAbs to STEAP2 was analysed by ELISA, Western blot and confocal microscopy. Results: IHC/TMA analysis showed low STEAP2 protein levels in 33 different organs across the human body. Structural analysis of STEAP2 identified five targetable domains (Peptides1 - 5) specific to the extracellular loops1 - 3 (ECL1 - 3) of STEAP2. Peptide5/ECL3, &#x201E;GWKRAFEEEYYRFY&#x201C;, appeared as the most promising immunogen region and was used as the antigen for mAb development. Anti-pAb treatment reduced cancer cell migration, invasion and viability of PC3 cells and triggered receptor internalisation of STEAP2. The anti-STEAP2- pADC was 3-fold more efficient than the unconjugated anti-STEAP2 pAb in decreasing the cell viability at a dose of 100 &#xB5;g/ml. Peptide5/ECL3 elicited a moderate immune response in Balb/C mice. Four anti-STEAP2 mAbs were developed and their specificity to STEAP2 was confirmed by ELISA. Conclusion: The low tissue expression profile of STEAP2 implies few off-target side-effects are likely to occur if STEAP2 is to be utilised as a future drug target. Peptide1 - 5 specific to the ECL1 - 3 of STEAP2 are potential antigen regions for future mAb development. When ECL3 was evaluated, the anti-STEAP2 pAb targeting this region was indeed capable of significantly reducing cancer invasive traits and triggered receptor internalisation in PC3 cells. Assessment of the anti-STEAP2 pADC demonstrated the potential utility of the ADC technology in the future. These promising findings highlight the therapeutic value of Ab-based strategies against STEAP2 to block cancer invasive traits. Evaluation of the four generated anti-STEAP2 mAbs indicated their specificity to STEAP2, albeit future validation is required. The in-vitro findings presented herein provide proof-of-concept, that supports STEAP2 as a viable drug target, with a focus on Abs and ADCs, prior to preclinical in-vivo studies for the treatment of patients with advanced prostate cancer.</abstract><type>E-Thesis</type><journal/><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher/><placeOfPublication>Swansea</placeOfPublication><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic/><keywords/><publishedDay>19</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-01-19</publishedDate><doi>10.23889/SUthesis.59217</doi><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><supervisor>Doak, Shareen H. ; Conlan, Steve</supervisor><degreelevel>Doctoral</degreelevel><degreename>Ph.D</degreename><apcterm/><lastEdited>2022-01-27T15:47:28.4614120</lastEdited><Created>2022-01-19T15:40:20.3976005</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>AI-MY</firstname><surname>CHI</surname><order>1</order></author></authors><documents><document><filename>Under embargo</filename><originalFilename>Under embargo</originalFilename><uploaded>2022-01-27T15:14:23.4264995</uploaded><type>Output</type><contentLength>6643396</contentLength><contentType>application/pdf</contentType><version>E-Thesis &#x2013; open access</version><cronfaStatus>true</cronfaStatus><embargoDate>2023-05-30T00:00:00.0000000</embargoDate><documentNotes>Copyright: The author, Aimy Nguyen Chi, 2020.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2022-01-27T15:47:28.4614120 v2 59217 2022-01-19 Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer a64c91cbb998dc0f5a14f291102f75ce AI-MY CHI AI-MY CHI true false 2022-01-19 Introduction: Prostate cancer is the second most frequent male cancer worldwide. Although prostate cancer is not always life-threatening when confined to the gland, the 5-year survival rate remains poor for men with advanced disease at approximately 30%. For such patients, there is an unmet need for patient-tailored drugs to improve their clinical management and quality of life, since current therapy options are accompanied with severe side-effects. The Six-Transmembrane Epithelial Antigen of the Prostate2 (STEAP2) is a cell surface protein highly expressed in advanced prostate cancer but not in the normal prostate. STEAP2 drives cancer invasive traits associated with prostate cancer progression in vitro and represents a promising drug target. The aim of this thesis was therefore to evaluate, whether STEAP2 is a viable drug target in vitro, with a focus on the application of antibodies (Abs) and Ab-Drug-Conjugates (ADCs), to treat advanced prostate cancer. Methods: Immunohistochemistry (IHC) analysis of tissue-microarrays (TMAs) containing 33 tissues across the human body was conducted to assess the normal tissue profile of STEAP2. Structural analysis of STEAP2 was performed to identify targetable regions for the use of Ab therapeutics. One commercial polyclonal anti-STEAP2 Ab (anti-STEAP2 pAb) was selected for proof-of-concept studies based on the ability to detect both linear and native STEAP2 by confocal microscopy and protein analysis in prostate cancer cells (PC3) and normal prostate epithelial cells (PNT2). The effect of the anti-STEAP2 pAb on cancer invasive traits was studied in PC3 and PNT2 cells. Receptor internalisation of STEAP2 was evaluated upon anti-STEAP2 pAb binding to confirm the suitability of the ADC technology by confocal microscopy. A polyclonal anti-STEAP2-monomethylauristatin-E (MMAE) ADC (anti-STEAP2 pADC) was produced to compare its effect on reducing the cell viability of PC3 cells versus the unconjugated anti-STEAP2 pAb alone. Monoclonal anti-STEAP2 Ab (anti-STEAP2 mAb) was generated by the hybridoma technology using Balb/C mice. The specificity of the mAbs to STEAP2 was analysed by ELISA, Western blot and confocal microscopy. Results: IHC/TMA analysis showed low STEAP2 protein levels in 33 different organs across the human body. Structural analysis of STEAP2 identified five targetable domains (Peptides1 - 5) specific to the extracellular loops1 - 3 (ECL1 - 3) of STEAP2. Peptide5/ECL3, „GWKRAFEEEYYRFY“, appeared as the most promising immunogen region and was used as the antigen for mAb development. Anti-pAb treatment reduced cancer cell migration, invasion and viability of PC3 cells and triggered receptor internalisation of STEAP2. The anti-STEAP2- pADC was 3-fold more efficient than the unconjugated anti-STEAP2 pAb in decreasing the cell viability at a dose of 100 µg/ml. Peptide5/ECL3 elicited a moderate immune response in Balb/C mice. Four anti-STEAP2 mAbs were developed and their specificity to STEAP2 was confirmed by ELISA. Conclusion: The low tissue expression profile of STEAP2 implies few off-target side-effects are likely to occur if STEAP2 is to be utilised as a future drug target. Peptide1 - 5 specific to the ECL1 - 3 of STEAP2 are potential antigen regions for future mAb development. When ECL3 was evaluated, the anti-STEAP2 pAb targeting this region was indeed capable of significantly reducing cancer invasive traits and triggered receptor internalisation in PC3 cells. Assessment of the anti-STEAP2 pADC demonstrated the potential utility of the ADC technology in the future. These promising findings highlight the therapeutic value of Ab-based strategies against STEAP2 to block cancer invasive traits. Evaluation of the four generated anti-STEAP2 mAbs indicated their specificity to STEAP2, albeit future validation is required. The in-vitro findings presented herein provide proof-of-concept, that supports STEAP2 as a viable drug target, with a focus on Abs and ADCs, prior to preclinical in-vivo studies for the treatment of patients with advanced prostate cancer. E-Thesis Swansea 19 1 2022 2022-01-19 10.23889/SUthesis.59217 COLLEGE NANME COLLEGE CODE Swansea University Doak, Shareen H. ; Conlan, Steve Doctoral Ph.D 2022-01-27T15:47:28.4614120 2022-01-19T15:40:20.3976005 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine AI-MY CHI 1 Under embargo Under embargo 2022-01-27T15:14:23.4264995 Output 6643396 application/pdf E-Thesis – open access true 2023-05-30T00:00:00.0000000 Copyright: The author, Aimy Nguyen Chi, 2020. true eng
title Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer
spellingShingle Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer
AI-MY CHI
title_short Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer
title_full Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer
title_fullStr Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer
title_full_unstemmed Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer
title_sort Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer
author_id_str_mv a64c91cbb998dc0f5a14f291102f75ce
author_id_fullname_str_mv a64c91cbb998dc0f5a14f291102f75ce_***_AI-MY CHI
author AI-MY CHI
author2 AI-MY CHI
format E-Thesis
publishDate 2022
institution Swansea University
doi_str_mv 10.23889/SUthesis.59217
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
description Introduction: Prostate cancer is the second most frequent male cancer worldwide. Although prostate cancer is not always life-threatening when confined to the gland, the 5-year survival rate remains poor for men with advanced disease at approximately 30%. For such patients, there is an unmet need for patient-tailored drugs to improve their clinical management and quality of life, since current therapy options are accompanied with severe side-effects. The Six-Transmembrane Epithelial Antigen of the Prostate2 (STEAP2) is a cell surface protein highly expressed in advanced prostate cancer but not in the normal prostate. STEAP2 drives cancer invasive traits associated with prostate cancer progression in vitro and represents a promising drug target. The aim of this thesis was therefore to evaluate, whether STEAP2 is a viable drug target in vitro, with a focus on the application of antibodies (Abs) and Ab-Drug-Conjugates (ADCs), to treat advanced prostate cancer. Methods: Immunohistochemistry (IHC) analysis of tissue-microarrays (TMAs) containing 33 tissues across the human body was conducted to assess the normal tissue profile of STEAP2. Structural analysis of STEAP2 was performed to identify targetable regions for the use of Ab therapeutics. One commercial polyclonal anti-STEAP2 Ab (anti-STEAP2 pAb) was selected for proof-of-concept studies based on the ability to detect both linear and native STEAP2 by confocal microscopy and protein analysis in prostate cancer cells (PC3) and normal prostate epithelial cells (PNT2). The effect of the anti-STEAP2 pAb on cancer invasive traits was studied in PC3 and PNT2 cells. Receptor internalisation of STEAP2 was evaluated upon anti-STEAP2 pAb binding to confirm the suitability of the ADC technology by confocal microscopy. A polyclonal anti-STEAP2-monomethylauristatin-E (MMAE) ADC (anti-STEAP2 pADC) was produced to compare its effect on reducing the cell viability of PC3 cells versus the unconjugated anti-STEAP2 pAb alone. Monoclonal anti-STEAP2 Ab (anti-STEAP2 mAb) was generated by the hybridoma technology using Balb/C mice. The specificity of the mAbs to STEAP2 was analysed by ELISA, Western blot and confocal microscopy. Results: IHC/TMA analysis showed low STEAP2 protein levels in 33 different organs across the human body. Structural analysis of STEAP2 identified five targetable domains (Peptides1 - 5) specific to the extracellular loops1 - 3 (ECL1 - 3) of STEAP2. Peptide5/ECL3, „GWKRAFEEEYYRFY“, appeared as the most promising immunogen region and was used as the antigen for mAb development. Anti-pAb treatment reduced cancer cell migration, invasion and viability of PC3 cells and triggered receptor internalisation of STEAP2. The anti-STEAP2- pADC was 3-fold more efficient than the unconjugated anti-STEAP2 pAb in decreasing the cell viability at a dose of 100 µg/ml. Peptide5/ECL3 elicited a moderate immune response in Balb/C mice. Four anti-STEAP2 mAbs were developed and their specificity to STEAP2 was confirmed by ELISA. Conclusion: The low tissue expression profile of STEAP2 implies few off-target side-effects are likely to occur if STEAP2 is to be utilised as a future drug target. Peptide1 - 5 specific to the ECL1 - 3 of STEAP2 are potential antigen regions for future mAb development. When ECL3 was evaluated, the anti-STEAP2 pAb targeting this region was indeed capable of significantly reducing cancer invasive traits and triggered receptor internalisation in PC3 cells. Assessment of the anti-STEAP2 pADC demonstrated the potential utility of the ADC technology in the future. These promising findings highlight the therapeutic value of Ab-based strategies against STEAP2 to block cancer invasive traits. Evaluation of the four generated anti-STEAP2 mAbs indicated their specificity to STEAP2, albeit future validation is required. The in-vitro findings presented herein provide proof-of-concept, that supports STEAP2 as a viable drug target, with a focus on Abs and ADCs, prior to preclinical in-vivo studies for the treatment of patients with advanced prostate cancer.
published_date 2022-01-19T04:16:21Z
_version_ 1763754095744647168
score 11.012924

Similar Items